GO
Loading...

Merck & Co Inc

More

  • Merck buys Swiss biotech with promising cancer drug Thursday, 18 Dec 2014 | 12:16 PM ET

    KENILWORTH, N.J.— Drugmaker Merck says it's bought a Swiss biotech company developing cancer drugs as part of its strategy to be a top player in cancer, one of the hottest pharmaceutical research areas. Merck& Co., based in Kenilworth, New Jersey, will pay up to $110 million upfront to OncoEthix. The privately held company could receive further payments of up to $265...

  • *Shares in GSK partner Agenus jump 10 percent. LONDON, Dec 18- An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. The data suggests the British company's new shot could be a strong competitor for Merck& Co's established vaccine...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • NEW YORK/ WASHINGTON, Dec 11- U.S. prosecutors, already smarting from a appeals court ruling that weakens their ability to crack down on future insider trading, on Thursday faced widening fallout from the decision as some existing cases threatened to unravel. Lawyers for some defendants hinted they might seek to withdraw guilty pleas, and a Manhattan federal...

  • New HPV vaccine strengthens cancer protection Wednesday, 10 Dec 2014 | 3:22 PM ET

    WASHINGTON— The drugmaker Merck& Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer. The FDA said Wednesday the updated Gardasil has the potential to prevent roughly 90 percent of cervical, vulvar, vaginal and anal cancers.

  • Merck advancing breast cancer drug to mid-stage Wednesday, 10 Dec 2014 | 12:54 PM ET

    TRENTON, N.J.— Drugmaker Merck& Co. said Wednesday that it will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type of breast cancer. Merck, based in Kenilworth, New Jersey, said it will start mid-stage patient tests of Keytruda in the first half of 2015. It's received accelerated...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Merck and Spirit Airlines are big market movers Tuesday, 9 Dec 2014 | 4:43 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. Merck& Co., down $1.87 to $60.01. T-Mobile US Inc., down $2.35 to $25.85.

  • Merck committed to Cubist after patent losses Tuesday, 9 Dec 2014 | 9:29 AM ET

    Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday. The court upheld one patent that would stave off a cheaper generic version of the drug from rival Hospira Inc. until...

  • McDonald's and Sony are big market movers Monday, 8 Dec 2014 | 4:41 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. McDonald's Corp., down $3.70 to $92.61. Sony Corp., down $1.01 to $21.15.

  • $9.5 billion blockbuster drug deal  Monday, 8 Dec 2014 | 1:01 PM ET

    Following Merck's acquisition of Cubist, chairman and CEO Kenneth Frazier discusses innovation possibilities the deal presents for public health, with CNBC's Meg Tirrell.

  • Cubist options unusually active before Merck deal Monday, 8 Dec 2014 | 12:50 PM ET

    NEW YORK, Dec 8- Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck& Co will buy Cubist for a hefty premium. Merck said it will pay $102 a share for Cubist, 37 percent above the Lexington, Massachussetts, company's closing share price of $74.36 on Friday. Implied volatility jumped to...

  • NEW YORK, Dec 8- U.S. stocks were little changed on Monday, as investors weighed the strength of the U.S. economy against global growth concerns following soft data out of China and Japan, while biotechs rose on merger activity. Major indexes opened slightly lower after data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7...

  • Merck CEO: Biotech valuations reflect optimism  Monday, 8 Dec 2014 | 10:17 AM ET

    Merck agreed to acquire Cubist Pharmaceuticals in a $9.5 billion deal. CNBC's Meg Tirrell discusses the price of the deal and patent challenges Merck may face.

  • NEW YORK, Dec 8- U.S. stocks dipped on Monday, after soft data in China and Japan raised global growth concerns, while a further drop in oil prices weighed on energy shares. Data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.

  • Merck CEO: Examining wide range of opportunities  Monday, 8 Dec 2014 | 9:37 AM ET

    CNBC's Meg Tirrell provides the latest details on Merck's acquisition of Cubist Pharmaceuticals.

  • NEW YORK, Dec 8- U.S. stocks were poised for a lower open on Monday, putting the S&P 500 on track to pull back from its latest record high, as soft data in China and Japan kindled global growth concerns. Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in...

  • Merck-Cubist deal about 'superbugs'  Monday, 8 Dec 2014 | 9:09 AM ET

    CNBC's David Faber and Jim Cramer discuss Merck's acquisition of Cubist Pharmaceuticals for $8.4 billion in cash plus $1.1 billion in debt.